Pfizer Inc. said the U.S. Food and Drug Administration's Arthritis Advisory Committee voted 10 to 1 to recommend approval of Xeljanz to treat adults with active psoriatic arthritis.

The company's supplemental new drug application for the indication is under review by the FDA, with a decision expected by December.

Xeljanz is currently approved to treat adults with moderately to severely active rheumatoid arthritis.